US EditionNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
- Neurocrine Biosciences presented a systematic literature review on May 14, 2025, in San Diego analyzing high-dose glucocorticoids in congenital adrenal hyperplasia patients.
- The review followed from longstanding use of high-dose glucocorticoids to manage CAH, a lifelong genetic condition causing adrenal androgen excess and cortisol deficiency.
- The most frequently reported outcomes in the reviewed studies were related to bone health , cardiometabolic factors , and parameters of height and growth . A majority of the research demonstrated a significant correlation between glucocorticoid dosage and negative clinical effects.
- Over 98% of studies reporting significant links between glucocorticoid dosage and clinical outcomes identified that higher doses are associated with negative effects such as reduced bone density, greater insulin resistance, and increased body mass index.
- These findings emphasize the clinical burden of high-dose glucocorticoids in CAH and highlight emerging therapies that could reduce reliance on such doses, potentially improving patient outcomes.
Insights by Ground AI
Does this summary seem wrong?
44 Articles
44 Articles
All
Left
4
Center
14
Right
1
Aspen Daily News+3 Reposted by 3 other sources
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
Montana Standard+26 Reposted by 26 other sources
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical OutcomesFindings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
Coverage Details
Total News Sources44
Leaning Left4Leaning Right1Center14Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 21%
C 74%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage